Home » News » 12/05 » Novartis considers bid for Berna Biotech

Novartis considers bid for Berna Biotech

Date published: 20/12/2005

Novartis has announced that it will "explore the benefits" of acquiring the Swiss vaccines company Berna Biotech. The company said that it is looking at whether Berna could be combined with Chiron, a US vaccines company that Novartis is currently in the process of acquiring.

"The combination of Berna and Chiron offers complementary geographic coverage and product ranges as well as access to the attractive proprietary technology platforms of Berna," said Novartis in a statement.

Berna markets its core vaccine products in the field of hepatitis B/pediatric, respiratory and travel vaccines and has a broad development pipeline.

Crucell, a Dutch biotechnology company, announced on December 15th an offer to acquire Berna through an all-share exchange offer. In order to prepare a potential competing cash offer, Novartis has requested from and has been granted by Berna the opportunity to perform a due diligence investigation.

However, Novartis stressed that no decision had been reached on whether to make an offer for the firm.

© Adfero Ltd

Disclaimer

AllAboutMedicalSales excludes any warranty, express or implied, as to the quality, accuracy, timeliness, completeness or fitness for a particular purpose of this briefing. AllAboutMedicalSales will not be liable for any claims, penalties, losses, damages, costs, or expenses arising from the use of or inability to use this briefing or from any unauthorised access to or alteration of the Briefing. AllAboutMedicalSales makes no warranty that the contents of this briefing are compatible with all computer systems and browsers.